Original Research

Psychiatric Morbidity in Patients With Psoriasis

Author and Disclosure Information

 

References

Results

One hundred four participants were included in this study. The sociodemographic, clinical, and diagnostic profiles, as well as the determinants of MINI diagnosis, are provided in Tables 1 through 4. The PASI and DLQI scores indicated that most participants had mild to moderate psoriasis severity.10 The prevalence of alcohol-related disorders was only found in the male subpopulation, which is consistent with the sociocultural context of North India. Psoriasis severity (ie, PASI score) was not found to be a determinant of psychiatric diagnoses in the study population. There was no statistical difference in measures of current clinical status and treatment modality when those with or without any psychiatric diagnoses were compared. When the variables of disease duration, treatment duration, and DLQI were entered into a binary logistic regression with positive status for a MINI diagnosis as a dependent variable indicating the presence of a psychiatric disorder, it was found that the DLQI score was a significant predictor (b=0.19; SE=0.47; χ2=17.92; P<.05). This finding was the same for regression analyses for males and females separately and also for DD as a dependent variable.

Mean DLQI and PASI scores were positively correlated with each other (Pearson r=0.23; P=.01). This relationship was maintained in males (Pearson r=0.24; P=.03) but not in females (Pearson r=0.14; P=.30). The correlations between DLQI and PASI scores and both disease duration and treatment duration were not significant. The Cohen κ values for the interrater reliability analyses done to assess the concordance of the PHQ and MINI diagnostic groups were modest (0.31-0.42), which was true even when MINI depressive disorders without dysthymia and PHQ depressive disorders were compared.

Recommended Reading

Price Explosion
MDedge Dermatology
Step therapy and biologics: An easier road ahead?
MDedge Dermatology
VIDEO: Ken Gordon’s pro tips on using biologics in psoriasis
MDedge Dermatology
VIDEO: Humor, psychology turn noncompliance into better outcomes
MDedge Dermatology
SCCA2: Potential biomarker for psoriasis severity and treatment efficacy
MDedge Dermatology
Biosimilar infliximab gains FDA Advisory Committee endorsement
MDedge Dermatology
House panel says Medicare biosimilar payment plan will stifle innovation
MDedge Dermatology
Psoriasis for Seniors
MDedge Dermatology
Addressing Patient Concerns on Biologics for Psoriasis
MDedge Dermatology
VIDEO: IL-17 antagonists continue reshaping psoriasis therapy in 2016
MDedge Dermatology

Related Articles